1. Wolf PA, D'Agostino RB, Belanger AJ, et al.: Probability of stroke: a risk profile
from the Framingham Study. Stroke. 1991; 22: 312-318.

2. Savage PJ: Cardiovascular complications of diabetes mellitus. What we know and
what we need to know about their prevention. Ann Int Med 1996; 124: 123-126.

3. Neaton JD, Wentworth DN, Cutler J, Stamler J, Kuller L: Risk factors for death
from different types of stroke. Multiple Risk Factor Intervention Trial Research
Group. Ann Epidemiol. 1993 Sep; 3 (5): 493-9.

4. Abbott RD, Donahue RP, MacMahon SW, Reed DM, Yano K: Diabetes and the
risk of stroke. The Honolulu Heart Program. JAMA 1987; 257; 949-952.

5. Stegmayr B, Asplund K: Diabetes as a risk factor for stroke. A population
perspective. Diabetologia. 1995 Sep; 38 (9): 1061-8.

6. Asplund K, Hagg E, Helmers C et al.: The natural history of stroke in diabetic
patients. Acta Medi Scand 1980; 207: 417-424.

7. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, Glahn J,
Brandt T, Hacke W, Diener HC: Risk factors, outcome, and treatment in sub-
types of ischemic stroke: the German stroke data bank.
Stroke. 2001 Nov; 32 (11): 2559-66.

8. Prospective Studies Collaboration: Cholesterol, diastolic blood pressure, and
stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts.
Lancet 1995; 346: 1647-1653.

9. Rodriguez BL, D'Agostino R, Abbott RD, Kagan A, Burchfiel CM, Yano K,
Ross GW, Silbershatz H, Higgins MW, Popper J, Wolf PA, Curb JD:
Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program
and the Framingham Study: A comparison of incidence and risk factor effects.
Stroke. 2002 Jan; 33 (1): 230-6.

10. Amarenco P: Hypercholesterolemia, lipid-lowering agents, and the risk for
brain infarction. Neurology. 2001; 57 (5 Suppl 2): S35-44. Review.

11. Iso H, Jacobs DR Jr, Wentworth D, et al.: Serum cholesterol levels and six-year
mortality from stroke in 350,977 men screened for the Multiple Risk Factor
Intervention Trial. N Engl J. Med. 1989; 320: 904-910.

12. Lehto S, Ronnemaa T, Pyorala K, Laakso M: Predictors of stroke in middle-aged
patients with non-insulin-dependent diabetes. Stroke. 1996 Jan; 27 (1): 63-8.

13. Davis TME, Millns H, Stratton IM, Holman RR, Turner RC: Risk factors for stroke in
type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29.
Arch Int Med 1999; 159: 1097-1103.

14. Klein R, Moss R: A comparison of the study population in the diabetes control
and complication trial and a wisconsin epidemiologic study of diabetic retino-
pathy. Arch Int Med 1995; 155: 745-754.

15. The DECODE Study Group, the European Diabetes Epidemiology Group: Glucose
tolerance and cardiovascular mortality: comparison of fasting and 2-hour diag-
nostic criteria. Arch Int Med 2001; 161: 397-405.

16. Sen S, Stephen M. Oppenheimer JL, and Cohen B: Risk Factors for Progression of
Aortic Atheroma in Stroke and Transient Ischemic Attack Patients.
Stroke, Apr 2002; 33: 930-935.

17. Spoelstra-de Man AM, Brouwer CB, Stehouwer CD, Smulders YM:
Rapid progression of albumin excretion is an independent predictor of cardio-
vascular mortality in patients with type 2 diabetes and microalbuminuria.
Diabetes Care. 2001 Dec; 24 (12): 2097-101.

18. The Diabetes Control and Complications Trial Research Group: The Effect of
Intensive Treatment of Diabetes on the Development and Progression of
Long-Term Complications in Insulin-Dependent Diabetes Mellitus.
N Engl J Med, Sep 1993; 329: 977-986.

19. Source 1:
Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y,
Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of
diabetic microvascular complications in Japanese patients with non-insulin-
dependent diabetes mellitus: a randomized prospective 6-year study.
Diabetes Res Clin Pract. 1995 May; 28 (2): 103-17.
Source 2:
Shichiri M, Kishikawa H, Ohkubo Y, Wake N: Long-term results of the Kumamoto
Study on optimal diabetes control in type 2 diabetic patients.
Diabetes Care. 2000 Apr; 23 Suppl 2: B21-9.

21. United Kingdom Prospective Diabetes Study Group: Effect of intensive blood-
glucose control with metformin on complications in overweight patietns with
type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.

22. United Kingdom Prospective Diabetes Study Group: Efficacy of atentolol and
captopril in reducing risk of macrovascular and microvascular complications in
type 2 diabetes: UKPDS 39: BMJ 1998; 317: 713-720.

23. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of
macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.
BMJ 1998; 317: 703-713.

24. Adler AI, Stratton IM, Neil AW et al. on behalf of the UK Prospective Diabetes
Study Group: Association of systolic blood pressure with macrovascular and
microvascular complications of type 2 diabetes (UKPDS 36): prospective obser-
vational study. BMJ 2000; 321: 412-419.

25. Staessen JA, Wang J-G, Thijs L: Cardiovascular protection and blood pressure
reduction: a meta-analysis. Lancet 2001; 358: 1305-1315.

26. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research
Group: Major cardiovascular events in hypertensive patients randomized to
doxazosin vs. chlorthalidone: the antihypertensive and lipid-lowering treatment
to prevent heart attack trial (ALLHAT). JAMA 2000, Apr 19; 283 (15): 1967-75.

27. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive
drug treatment in older patients with isolated systolic hypertension: final
results of the Systolic Hypertension in the Elderly Program (SHEP).
JAMA 1991; 265: 3255-3264.

28. Curb JD, Pressel SL, Cutler JA, et al.: Effect of diuretic-based antihypertensive
treatment on cardiovascular disease risk in older diabetic patients with isolated
systolic hypertension: Systolic Hypertension in the Elderly Program Cooperative
Research Group. JAMA 1996; 276: 1886-1892.

29. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J,
Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering
and low-dose aspirin in patients with hypertension: principal results of the
Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
Lancet 1998, Jun 13; 351 (9118): 1755-62.

30. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW:
The effect of nisoldipine as compared with enalapril on cardiovascular outcomes
in patients with non-insulin-dependent diabetes and hypertension.
N Engl J Med. 1998, Mar 5; 338 (10): 645-52.

31. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A,
Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE:
Effect of angiotensin-converting-enzyme inhibition compared with conventional
therapy on cardiovascular morbidity and mortality in hypertension: the Captopril
Prevention Project (CAPPP) randomised trial.
Lancet 1999, Feb 20; 353 (9153): 611-6.

32. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F:
Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events
Randomized Trial (FACET) in patients with hypertension and NIDDM.
Diabetes Care 1998, Apr; 21 (4): 597-603.

33. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD:
Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in
patients with type 2 diabetes. Diabetes Care. 2000 Jul; 23 (7): 888-92.

34. Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure
control in normotensive type 2 diabetic patients on albuminuria, retinopathy
and strokes. Kidney Int. 2002, Mar; 61 (3): 1086-97.

35. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol
lowering in 4444 patients with coronary heart disease: the Scandinavian
Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.

36. Plehn JF, Davis BR, Sacks FM, et al.: Reduction of stroke incidence after myocar-
dial infarction with pravastatin: the Cholesterol and recurrent Events (CARE) study.
Circulation. 1999; 99: 216-223.

37. LIPID Study Group: Prevention of cardiovascular events and death with pravastatin
in patients with coronary heart disease and a broad range of initial cholesterol
levels: The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID)
study group. N Engl J Med. 1998; 339: 1349-1357.

38. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G:
Cholesterol lowering with simvastatin improves prognosis of diabetic patients
with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin
Survival Study (4S). Diabetes Care 1997, Apr; 20 (4): 614-20.

39. Haffner SM, Ashraf T: Predicting risk reduction of coronary disease in patients
who are glucose intolerant: a comparison of treatment with fenofibrate and
other lipid-modifying agents. Manag Care Interface 2000, Mar; 13 (3): 52-8.

40. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR,
Cole TG, Pfeffer MA, Braunwald E: Cardiovascular events and their reduction with
pravastatin in diabetic and glucose-intolerant myocardial infarction survivors
with average cholesterol levels: subgroup analyses in the cholesterol and recur-
rent events (CARE) trial. Circulation 1998, Dec 8; 98 (23): 2513-9.

41. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E,
Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary pre-
vention of coronary heart disease in men with low levels of high-density lipo-
protein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol
Intervention Trial Study Group. N Engl J Med. 1999, Aug 5; 341 (6): 410-8.

42. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A,
Chaitman BR, Leslie S, Stern T: Myocardial Ischemia Reduction with Aggressive
Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on
early recurrent ischemic events in acute coronary syndromes: the MIRACL study:
a randomized controlled trial. JAMA 2001, Apr 4; 285 (13): 1711-8.

43. Metaanalysis of ASA: Hart RG et al.: Arch Neurol 2000; 57: 326-332.

44. Harbison JW: Ticlopidine versus aspirin for the prevention of recurrent stroke.
Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study.
Stroke 1992, Dec; 23 (12): 1723-7.

45. Gent M, Blakely JA, Easton JD: The Candaian American Ticlopidine Study (CATS)
in thromboembolic stroke. Lancet 1989; 1: 1215-1220.

46. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus
aspirin in patients at risk of ischemic events (CAPRIE).
Lancet 1996; 348: 1329-1339.

47. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril
on cardiovascular and microvascular outcomes in people with diabetes mellitus:
results of the HOPE study and MICRO-HOPE substudy.
Lancet 2000; 355: 253-259.

48. PROGRESS COLLABORATIVE GROUP: Randomised trial of perindopril-base blood-
pressure-lowering regimen among 6105 individuals with previous stroke or
transient ischaemic attack. Lancet 2001; 358: 1033-1041.

49. Lewis EJ, Hunsicker LG, Clarke WR et al. for the COLLABORATIVE STUDY GROUP:
Renoprotective effect of the antiotensin-receptor antagonist irbesartan in patients
with nephropathy due to type 2 diabetes. New Engl J Med 2001; 345: 851-860.

50. Brenner BM, Cooper ME, De Zeeuw D et al.: Effects of losartan on renal and
cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
N Engl J Med 2001; 345: 861-869.

51. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P: Antithrombotic and throm-
bolytic therapy for ischemic stroke: Sixth ACCP Consensus Conference on Anti-
thrombotic Therapy. Chest 2001; 119: 300S-320S.

52. Wardlaw JM: Overview of Cochrane thrombolysis meta-analysis.
Neurology 2001; 57 (Suppl 2): S69-S76.

53. International Stroke Trial Collaborative Group: The International Stroke Trial
(IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither
among 19,435 patients with acute ischemic stroke. Lancet 1997; 349: 1569-1581.

54. Chinese Acute Stroke Trial (CAST) Collaborative Group: CAST: a randomized pla-
cebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic
stroke. Lancet 1997; 349: 1641-1649.

55. Donnan GA, Davis SM: Thrombolysis in acute ischaemic stroke (review).
J of Clinical Neuroscience 2001; 8: 112-115.

56. Hankey GJ: Thrombolysis for acute ischaemic stroke (review) J of Clinical Neuro-
science 2001; 8: 103-105.

57. Goldstein LB: Medical Therapy for acute ischemic stroke (review).
Current Atherosclerosis Reports 2001; 3: 299-306.

58. Warach S: New imaging strategies for patient selection for thrombolytic and
neuroprotective therapies (review). Neurology 2001; 75 (Suppl 2): S48-S52.

59. Lev MH, Farkas J, Rodriguez VR et al.: CT angiography in the rapid triage of
patients with hyperacute stroke to intraarterail thrombolysis: accuracy in the
detection of large vessel thrombus.
J of Comp Assisted Tomography 2001; 25: 520-528.

60. Silver B, Demaerschalk B, Merino JG et al.: Improved outcomes in stroke throm-
bolysis with pre-specified imaging criteria.
Canadian J of Neurological Sciences 2001; 28: 113-119.

61. Hoggard N, Wilkinson ID, Griffiths PD: The imaging of ischaemic stroke (review).
Clinical Radiology 2001; 56: 171-183.

62. Pillai JJ, Lanzieri CF, Trinidad SB et al.: Initial angiographic appearance of intra-
cranial vascular occlusions in acute stroke as a predictor of outcome of throm-
bolysis: initial experience. Radiology 2001; 218: 733-738.

63. Koennecke HC, Nohr R, Leistner S, Marx P: Intravenous tPA for ischemic stroke
team performance over time, safety, and efficacy in a single-center, 2-year
experience. Stroke 2001; 1074-1078.

64. Pereira AC, Martin PJ, Warburton EA: Thrombolysis in acute ischaemic stroke
(review). Postgrad M Journal 2001; 77: 166-171.